A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects

NCT07280013 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma (MM)

Interventions

DRUG: Cemsidomide
BIOLOGICAL: Elranatamab

Sponsor

C4 Therapeutics, Inc.